Journal article
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells
Leukemia & lymphoma, Vol.56(7), pp.2146-2152
07/2015
DOI: 10.3109/10428194.2014.981172
PMID: 25373508
Abstract
Double hit lymphoma (DHL) is a recently recognized lymphoma with a survival of less than 2 years. Both ABT-737, a Bcl-2/Bcl-XL inhibitor, and ABT-199, which selectively targets Bcl-2, were potently cytotoxic against DHL cell lines Sc-1 and OcI-LY18, the RL cell line and primary human DHL cells, but not Ramos cells, which lack Bcl-2 expression. ABT-199 was more potent than ABT-737, and is the most promising of the BH3 mimetics to date. The DHL cell lines were also sensitive (< 200 nM) to doxorubicin, methotrexate, cytarabine and the proteosome inhibitor, bortezomib. The combination of chemotherapy with ABT-199 and doxorubicin or cytarabine, bortezomib, YM-155 and JQ1 produced synergistic cell kill against the DHL cell lines. Cells from a patient with DHL were also sensitive to JQ1 and bortezomib, providing a rationale for a clinical trial of these combinations in patients with relapsed DHL.
Details
- Title: Subtitle
- ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells
- Creators
- Nadine Johnson-Farley - Rutgers Cancer Institute of New Jersey and the Robert Wood Johnson School of Medicine , New Brunswick, NJ , USAJonny VelizS BhagavathiJoseph R Bertino
- Resource Type
- Journal article
- Publication Details
- Leukemia & lymphoma, Vol.56(7), pp.2146-2152
- Publisher
- United States
- DOI
- 10.3109/10428194.2014.981172
- PMID
- 25373508
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Grant note
- P30 CA072720 / NCI NIH HHS
- Language
- English
- Date published
- 07/2015
- Academic Unit
- Pathology
- Record Identifier
- 9984047621702771
Metrics
21 Record Views